EPIDERMAL GROWTH FACTOR STIMULATES WOUND HEALING IN VIVO

目前还没有已知的药物可以加速和改善 活体人体伤口愈合的质量。在前期工作中 重组EGF促进实验和实验质量的提高 人类的伤口愈合。现在，毫克量的EGF是 有可能确定EGF和EGF的机制 相关生长因子在体内影响创面愈合。这 应用程序将研究调节生长和 哺乳动物皮肤的增殖与伤口愈合有关 在活体猪模型中，以及在可能的情况下在人类患者中。 具体目标是：1)推广组织化学、EM和 应用EGF及其受体进行形态计量学研究 该因子参与猪和人的伤口愈合；2) 确定细胞的顺序外观和身份 在伤口愈合过程中被EGF和其他生长因子激活 使用结合、磷酸化和原位放射自显影；3) 原位杂交法检测创面愈合过程中是否存在EGF-R 受受体占位、配体(EGF、转化生长因子-A)或 与其他因素(转化生长因子-β)的相互作用；4)研究 表皮生长因子及其相关因素对上皮和间充质的影响 通过研究序列的出现、分布和相互作用 和细胞外基质成分即胶原蛋白的性质 和纤维连接蛋白。

No pharmacologic agent is known to accelerate and improve the quality of human wound healing in vivo. In preliminary work recombinant EGF accelerated the quality of experimental and human wound healing. Now that milligram quantities of EGF are available it is possible to determine mechanisms whereby EGF and related growth factors affect wound healing in vivo. This application will study processes mediating growth and proliferation of mammalian skin as they relate to wound healing in an in vivo porcine model and where possible in human patients. The specific aims are: 1) To extend histochemical, EM and morphometric studies using EGF and its receptor to define involvement of this factor in porcine and human wound healing; 2) To determine the sequential appearance and identity of cells activated during wound healing by EGF and other growth factors using binding, phosphorylation, and in situ autoradiography; 3) To determine by in situ hybridization if EGF-R during wound healing is modulated by receptor occupancy, ligand (EGF, TGF-A) or interactions with other factors (TGF-B); 4) To study the effects of EGF and related factors on epithelial and mesenchymal interactions by studying the sequential appearance, distribution and nature of extracellular matrix components namely collagens and fibronectin.